Imagine bones that fracture from a sneeze. Bones that break during a diaper change. Bones that crack from the ordinary forces of childhood – a tumble, a hug, a stumble on flat ground. For individuals living with osteogenesis imperfecta, this is not a metaphor. It is daily reality.
Osteogenesis imperfecta (OI) – commonly called brittle bone disease – is one of the most challenging rare skeletal disorders in medicine. It is a genetic condition rooted in a fundamental defect in type I collagen, the most abundant structural protein in bone, skin, ligaments, and connective tissue. When this protein is deficient or structurally abnormal, the entire skeletal architecture is compromised.
Yet OI is not simply a bone disease. It is a systemic connective tissue disorder that touches growth, hearing, dentition, vision, and mobility. Understanding how it works – and what can be done – is the first step toward genuinely better outcomes. This article walks through the science, the clinical spectrum, the impact on daily life, and the most current thinking on management, including both modern medicine and traditional supportive strategies.
What Is Osteogenesis Imperfecta? The Genetic Root of the Problem
At the molecular level, OI is a disease of collagen biosynthesis failure. Approximately 85-90% of all OI cases are caused by mutations in COL1A1 and COL1A2 – the two genes that encode the alpha chains of type I collagen. Together, two alpha-1 chains and one alpha-2 chain twist into the triple-helix structure that gives bone its tensile strength. When either gene is mutated, this triple helix is either produced in insufficient quantities or assembled in a structurally defective form.
The consequence is bone matrix that cannot bear normal mechanical loads. Normal bone matrix is composed of approximately 90% type I collagen fibers, with the remaining 10% consisting of non-collagenous proteins. When this scaffold is compromised, even the mineralization process – where calcium and phosphate crystals are deposited into the collagen web – cannot compensate. The result is a skeleton that is both structurally fragile and mechanically inferior.
OI follows an autosomal dominant inheritance pattern in the majority of cases, meaning a single mutated copy of COL1A1 or COL1A2 is sufficient to cause the condition. However, some severe types – particularly Types II and III – can arise from new spontaneous mutations with no family history.
Find out more about how collagen deficiency affects bones and joints in this clinical overview on SVK Herbal’s resource library.
The Five Types of OI: A Spectrum From Mild to Lethal
OI is not one disease – it is a spectrum. The Sillence classification system organizes it into five primary types, each with distinct severity, prognosis, and management needs.
Type I – The Mildest Form
Type I OI is the most common and mildest presentation. It results from haploinsufficiency – the COL1A1 gene produces approximately 50% of normal type I collagen, but what is produced is structurally normal. Individuals with Type I OI experience a higher-than-normal fracture rate but rarely develop significant skeletal deformities. They typically have blue sclerae (a bluish tint to the whites of the eyes), and hearing loss develops in adulthood in a significant proportion of patients. Height is often normal or near-normal.
Type II – Perinatal Lethal
Type II is the most severe form of OI, and most affected infants do not survive. Bones are so fragile that fractures occur in utero. Multiple rib fractures compromise respiratory function from birth, and the skull is poorly mineralized. This type is most often caused by new mutations in COL1A1 or COL1A2 and is rarely inherited from an affected parent.
Type III – Progressively Deforming
Type III OI is the most severe form compatible with survival. It causes severe, progressive skeletal deformities with fractures beginning before birth and continuing throughout life. Significant growth restriction, kyphoscoliosis, and limb bowing are characteristic. Many individuals with Type III OI require wheelchair use for mobility. This type carries the heaviest burden of chronic pain and physical limitation.
Type IV – Moderate Severity
Type IV OI sits between Types I and III in severity. Sclerae are typically white or near-white rather than blue, and fracture frequency is intermediate. Skeletal deformities are variable. Short stature is common but not always severe. Dentinogenesis imperfecta – abnormal tooth formation – is frequent in this type.
Type V – Distinctive Features
Type V OI is clinically distinguishable by radial head dislocation and ossification of the interosseous membrane between the radius and ulna, producing a characteristic interosseous membrane calcification on imaging. Sclerae are white and dentinogenesis imperfecta is absent. It is caused by mutations in genes outside COL1A1/COL1A2, specifically affecting the IFITM5 gene.
How OI Damages Bone Structure
Understanding what goes wrong in OI bone requires a brief look at normal bone biology. Healthy bone formation involves two key steps. First, osteoblasts – bone-building cells – secrete a protein scaffold made primarily of type I collagen called osteoid. Second, calcium and phosphate crystals are deposited into this scaffold to form hydroxyapatite – the mineral that makes bone hard and rigid.
In OI, the first step is compromised. The collagen scaffold itself is either insufficient in quantity (Type I) or structurally abnormal (Types II, III, IV). When structurally abnormal collagen is laid down, the mineralization process proceeds, but builds on a defective foundation. The result is bone that is:
- Brittle – it breaks under forces that healthy bone easily tolerates
- Poorly remodeled – the constant turnover of bone tissue is dysregulated
- Thin-cortexed – the outer hard shell of bone (cortex) is significantly thinner than normal
- Worm-eaten in appearance – wormian bones (extra small bones within the skull sutures) are a hallmark finding on imaging
Fractures in OI patients can occur in any bone, but are most common in the long bones of the extremities – the femur, tibia, humerus, radius, and ulna. Vertebral compression fractures are also common, particularly in more severe types, and contribute heavily to the characteristic short stature and spinal deformity seen in OI.
The Impact on Growth and Stature
Growth restriction is one of the most visible consequences of OI, particularly in moderate to severe types. It occurs through several interconnected mechanisms.
Growth Plate Vulnerability
Fractures at or near the growth plates – the cartilaginous zones at the ends of long bones where longitudinal growth occurs – can permanently disrupt normal growth. Each fracture near a growth plate carries the risk of growth arrest or angular deformity as the bone heals in an abnormal position.
Vertebral Compression and Spinal Deformity
Vertebral compression fractures collapse the height of individual vertebrae, progressively reducing spinal height even when long bone growth is relatively preserved. The cumulative effect of multiple vertebral fractures through childhood produces the significant height loss seen in moderate-to-severe OI. Scoliosis and kyphosis – sideways and forward curvature of the spine – compound this effect, further reducing standing height and negatively affecting respiratory mechanics.
Bowing Deformities
Long bone bowing is a characteristic feature of moderate and severe OI. Repeated microfractures and stress injuries cause bones to heal in progressively bowed configurations. The femur and tibia are most commonly affected, producing a waddling gait and progressively reducing the mechanical efficiency of the lower limb. Bowing itself weakens the bone further by changing the distribution of mechanical stress, creating a self-reinforcing cycle of deformity and fracture risk.
Muscle Weakness – A Hidden Contributor
An often-overlooked aspect of OI is that muscle weakness is an intrinsic feature of the condition, not merely a consequence of immobility. Type I collagen is present in muscle fascia and connective tissue, and its deficiency may directly impair muscle fiber architecture. Combined with the inevitable deconditioning from fracture-related immobilization, this produces the characteristic muscle weakness that compounds mobility challenges in OI patients.
How OI Affects Mobility
Mobility impairment in OI is complex, multifactorial, and varies enormously across the disease spectrum. Understanding it requires looking at both the structural and functional dimensions.
Fracture Frequency and Functional Loss
Fractures in OI patients can be triggered by minimal or absent trauma – rolling over in bed, being lifted, or sustaining a minor fall that healthy individuals would walk away from without injury. Each fracture requires immobilization for healing, during which muscle strength, cardiovascular fitness, and bone density all decline further. This cycle of fracture, immobilization, and deconditioning is a major driver of progressive functional decline in severe OI.
Joint Hypermobility – The Paradox
OI presents a paradox: bones are fragile and rigid in fracture risk, yet joints are often hypermobile. Joint hypermobility and increased joint laxity are consistently reported in OI, reflecting the widespread deficiency of type I collagen in ligaments, joint capsules, and connective tissue. Hypermobile joints are less stable, more prone to subluxation, and less effective at absorbing impact forces – which shifts more mechanical stress onto already fragile bone. The combination of bone fragility and joint instability creates a uniquely challenging functional profile.
Find out more about connective tissue resilience and ligament health in this SVK Herbal deep dive on collagen and structural tissue repair.
Pain as a Mobility Barrier
Chronic bone pain is a major but underappreciated symptom in OI across all types and severity levels. Even in the absence of acute fracture, OI patients experience background pain from microtrauma, bony deformity, muscle tension compensating for structural instability, and the chronic low-grade inflammatory state associated with abnormal bone remodeling. This pain is not simply a symptom to be managed – it is a significant barrier to the physical activity that OI patients need for bone stimulation, muscle maintenance, and cardiovascular health.
Ambulatory Status
Ambulatory status in OI varies dramatically by type. Most individuals with Type I OI ambulate independently. Type IV OI patients may ambulate with or without assistive devices depending on fracture history and deformity severity. Type III OI patients most commonly use wheelchairs, though some achieve household ambulation with specialized orthotics and careful surgical management. The goal of modern OI management is to maximize and preserve ambulatory function for as long as possible.
Beyond Bones: The Systemic Manifestations of OI
OI’s impact extends well beyond the skeleton, reflecting the ubiquitous distribution of type I collagen throughout the body.
Hearing Loss
Hearing loss affects up to 70% of all OI patients across all clinical types. It typically presents in the second and third decades of life. The etiology is complex, involving both conductive components (from ossicular chain abnormalities in the middle ear) and sensorineural components from cochlear damage. Regular audiological assessment is an essential part of OI follow-up.
Dentinogenesis Imperfecta
Dentinogenesis imperfecta (DI) is a genetic disorder of tooth development seen in a significant proportion of OI patients. Teeth appear gray or brown with a translucent quality and wear down or fracture easily. DI can affect both primary and permanent dentition, creating significant oral health challenges that require specialized dental management from early childhood.
Blue Sclerae
Blue or gray-blue sclerae – the bluish tint to the whites of the eyes – is one of the most recognizable signs of OI. It results from thinner-than-normal scleral tissue, through which the underlying dark uveal tissue is visible. Blue sclerae are most pronounced in Type I OI and may fade with age.
Cardiovascular Involvement
Less commonly recognized but clinically important, OI can involve the cardiovascular system. Some patients develop aortic root dilation and valvular insufficiency due to type I collagen deficiency in the aortic wall and cardiac valves. This requires cardiac surveillance in patients with more severe forms of OI.
Respiratory Complications
In severe OI, particularly Type III, thoracic scoliosis and rib deformities restrict chest expansion and reduce respiratory reserve. Recurrent pneumonia and progressive respiratory insufficiency can become life-limiting in the most severely affected individuals. Respiratory assessment and management become increasingly important with age in severe OI.
Modern Medical Management of OI
Bisphosphonate Therapy – The Cornerstone
Bisphosphonates – drugs that inhibit osteoclast-mediated bone resorption – are the most widely used pharmacological treatment for OI. By slowing bone breakdown, they allow gradual accumulation of bone mineral density. Bisphosphonates have been shown to consistently improve bone mineral density in OI patients and, in growing children, help reshape vertebrae that have undergone compression fracture deformity. Intravenous pamidronate and zoledronic acid are most commonly used in pediatric OI; oral alendronate is an alternative for milder cases.
Emerging Biological Therapies
Beyond bisphosphonates, newer strategies including sclerostin inhibitory antibodies (romosozumab) are under investigation for OI. By blocking sclerostin – a protein that inhibits bone formation – these agents stimulate new bone building rather than merely slowing breakdown. Early case reports show meaningful bone mineral density gains in OI patients, though larger trials are ongoing.
Orthopedic Surgery – Rodding Procedures
Intramedullary rodding – the surgical insertion of metal rods inside long bones to provide internal scaffolding – is a cornerstone of orthopedic management in moderate and severe OI. Telescoping rods that grow with the child are preferred, reducing the need for repeated surgeries. Rodding stabilizes bowed bones, prevents progressive deformity, and allows more functional use of the limb.
Physical Therapy and Aquatic Rehabilitation
Targeted physical therapy is essential for maintaining muscle strength, mobility, and bone stimulation in OI without exposing patients to unacceptable fracture risk. Aquatic therapy is particularly valuable – water buoyancy reduces the mechanical load on bones while allowing muscle strengthening and cardiovascular conditioning. Swimming and water-based exercises are among the safest and most effective physical interventions available. Find out more about rehabilitation strategies after bone and joint injuries in this SVK Herbal clinical guide.
Gene Therapy – The Future
CRISPR/Cas9 gene editing has been applied in preclinical models to correct the mutated COL1A1 gene in OI, restoring normal type I collagen expression and osteogenic differentiation in induced pluripotent stem cells. While gene therapy for OI remains experimental, it represents the most fundamentally curative direction for future treatment, targeting the root mutation rather than managing downstream consequences.
Nutritional and Natural Supportive Strategies
While no dietary intervention corrects the underlying genetic defect in OI, nutritional optimization genuinely matters for maximizing the functional capacity of deficient bone tissue and supporting the connective tissue environment.
Collagen Peptides and Bone Support
Type I collagen peptides taken orally have shown chondroprotective and anti-inflammatory effects in preclinical models and are increasingly studied as dietary support for skeletal health. While they cannot replace deficient endogenous collagen synthesis in OI, they provide the amino acid building blocks – particularly glycine, proline, and hydroxyproline – that support the connective tissue matrix throughout the body. Collagen peptide supplementation supports bone density repair, reduces inflammation, and improves joint elasticity – mechanisms relevant to OI’s multi-system connective tissue vulnerability.
Naturem Joints+ incorporates collagen peptides alongside traditional herbal ingredients including Drynaria Fortunei, Rhizoma Homalomena, and Tinospora Sinensis – a formulation grounded in both modern nutritional science and Vietnamese herbal medicine that supports bone health, joint function, and connective tissue resilience as part of a comprehensive musculoskeletal support strategy.
Vitamin D and Calcium – Non-Negotiable Foundations
Adequate vitamin D is essential for calcium absorption and mineralization of whatever collagen scaffold OI bones can produce. Deficiency compounds the already-compromised mineralization in OI. All OI patients should maintain optimal vitamin D status, typically through supplementation given the challenges many face with outdoor activity. Calcium from dietary sources – dairy, leafy greens, fortified foods – provides the mineral substrate for hydroxyapatite crystal formation.
Anti-Inflammatory Herbal Support
Chronic low-grade inflammation is a recognized feature of abnormal bone remodeling in OI. Herbal compounds with documented anti-inflammatory activity on bone and connective tissue pathways include Drynaria Fortunei (Gu Sui Bu) – a traditional bone-healing herb used for centuries in Chinese and Vietnamese medicine – and Clinacanthus Nutans, which has anti-inflammatory properties relevant to musculoskeletal tissues. Boswellia serrata’s 5-LOX inhibition and Curcumin’s NF-kB blockade represent the most clinically studied botanical anti-inflammatory strategies for bone and joint conditions.
Find out more about anti-inflammatory herbs for joint and bone health in this comprehensive clinical guide from SVK Herbal.
The HerbsOfVietnam Library documents the classical Vietnamese and Eastern herbal approaches to bone fragility, connective tissue weakness, and structural skeletal support in depth – providing valuable traditional context for those navigating OI alongside modern medical care.
Living With OI: Practical Considerations for Patients and Families
Safe Movement and Activity
Activity is not the enemy of OI – the right activity, done safely, is essential. Low-impact movement like swimming, water aerobics, and stationary cycling stimulates bone formation through mechanical loading while minimizing fracture risk. High-impact activities – contact sports, trampolining, downhill skiing – should be avoided. The goal is to find the widest possible range of safe movement, not to restrict all activity.
Assistive Technology and Orthotics
Orthotics to stabilize lax joints are a key component of OI mobility management. Custom ankle-foot orthoses (AFOs), knee supports, and spinal bracing support skeletal alignment and reduce stress on vulnerable bones. Wheelchairs and mobility aids should be viewed as enabling devices that expand independence – not limitations – for those who need them.
Multidisciplinary Care – Essential, Not Optional
A multidisciplinary approach to OI care is the clinical standard, encompassing endocrinology (for bone density management), orthopedics (for surgical needs), physical and occupational therapy (for mobility and function), audiology (for hearing monitoring), dentistry (for DI management), and psychology (for the significant mental health burden of living with a chronic, painful, visible condition). No single specialist can address OI’s full clinical complexity.
Pain Management
Pain management in OI requires a multimodal approach combining pharmacological options (analgesics, anti-inflammatory medications used judiciously), physical therapy techniques (heat, massage, gentle mobilization), psychological strategies (cognitive behavioral approaches for chronic pain), and activity modification. Treating OI pain effectively is not merely about comfort – it is about preserving the functional capacity and quality of life that enable patients to live fully.
Final Thoughts: OI Is a Systemic Condition That Demands a Systemic Response
Osteogenesis imperfecta challenges every assumption about what bones are, what they can withstand, and what “normal” childhood and adult life should look like. It forces patients, families, and clinicians to think creatively, collaboratively, and comprehensively.
The science has advanced enormously – from bisphosphonate therapy improving bone density in growing children, to rodding surgeries preserving ambulatory function, to early-stage gene therapy offering a glimpse of future cure. Emerging treatments including sclerostin inhibitors are expanding the therapeutic toolkit beyond what was available even a decade ago.
Meanwhile, nutritional optimization, targeted physical therapy, anti-inflammatory herbal support, and traditional medicine perspectives all offer meaningful complementary contributions – not to replace medical treatment, but to maximize the functional capacity of every patient living with this condition.
For those navigating OI – whether as a patient, a parent, or a clinician – the message from both modern science and traditional medicine is consistent: the skeleton responds to what you give it. Give it the structural building blocks, the mechanical stimulation, the anti-inflammatory environment, and the multidisciplinary support it needs. And never stop looking for better answers.
For more expert guidance on bone health, connective tissue support, and natural wellness strategies, explore the clinical resource library at SVK Herbal.
This article is for informational and educational purposes only and does not constitute medical advice. Osteogenesis imperfecta requires diagnosis and management by qualified medical specialists. Always consult a healthcare professional before making decisions about treatment, supplementation, or physical activity.
Frequently Asked Questions (FAQs)
No. OI is a systemic connective tissue disorder, not just a bone disease. Because type I collagen is present throughout the body – in ligaments, tendons, teeth, sclera, and the inner ear – its deficiency produces problems well beyond the skeleton. Up to 70% of OI patients develop hearing loss, typically appearing in early adulthood. Dentinogenesis imperfecta causes brittle, discolored teeth. Joint hypermobility and laxity add instability on top of bone fragility. Some patients develop aortic root dilation and cardiac valvular problems due to collagen deficiency in the heart and vessel walls. This is why multidisciplinary care – not just orthopedics alone – is the clinical standard. Find out more about connective tissue and collagen-related bone conditions in this SVK Herbal overview. (MedlinePlus – OI Genetics, 2024); (Merck Manual – OI, 2025); (NIH StatPearls – OI, 2023)
Yes – and exercise is actively recommended. The key is choosing the right type. Physical therapy and low-impact activity stimulate bone formation through mechanical loading while keeping fracture risk low. Aquatic therapy is particularly effective – water buoyancy reduces skeletal load while still building muscle and cardiovascular fitness. A structured physical therapy regimen is a core part of OI management alongside medication and surgery. High-impact and contact activities should be avoided. The goal is the widest possible range of safe movement – not restriction. Collagen peptide supplementation combined with exercise has also shown benefits for joint functionality and connective tissue recovery. Find out more about bone and joint rehabilitation strategies in this SVK Herbal clinical guide. (PMC – OI Fractures and Rehabilitation, 2022); (PMC – OI Physiotherapy Case, 2022); (PMC – Collagen Peptides and Exercise, 2021)
No – they manage it, they do not cure it. Bisphosphonates work by inhibiting osteoclast-mediated bone resorption, slowing the breakdown of bone to allow gradual mineral density accumulation. They consistently improve bone mineral density in OI patients and help reshape compressed vertebrae in growing children. However, their effect on reducing fracture rates is less conclusive and they do not correct the underlying collagen defect. Emerging therapies – particularly sclerostin inhibitors like romosozumab and early-stage CRISPR gene editing of COL1A1 – represent more fundamentally corrective directions for the future. (PMC – Bisphosphonates and OI Cochrane Review, 2019); (PMC – OI Clinical Features and Therapies, 2020); (PMC – Romosozumab in OI, 2023)
It cannot replace deficient endogenous collagen synthesis – but it provides meaningful nutritional support. Oral collagen peptides supply glycine, proline, and hydroxyproline – the key amino acids the body needs to build and repair connective tissue matrices. Randomized trials show collagen peptides significantly reduce exercise-related joint pain and improve joint functionality. Hydrolyzed collagen from sources such as crocodile bone extract has demonstrated high bioavailability and clinical tolerability in bone health studies. Naturem Joints+ combines collagen peptides with Drynaria Fortunei and other traditional bone-supporting herbs, offering a complementary nutritional strategy alongside medical treatment. (PMC – Collagen Peptides Systematic Review, 2021); (PMC – Collagen Peptides and Knee Pain RCT, 2021); (SVKHerbal – Osteoporosis and Traditional Medicine, 2025)
OI diagnosis relies on clinical findings, imaging, and genetic testing. Radiological hallmarks include low bone density, bowing deformities, wormian bones in the skull, and compression fractures. Genetic sequencing confirming COL1A1 or COL1A2 mutations provides definitive diagnosis in most cases. However, OI is frequently misdiagnosed – most critically, it can be mistaken for child abuse when unexplained fractures appear in infants, with serious legal consequences. It can also be confused with rickets, osteomalacia, and idiopathic juvenile osteoporosis. Early, accurate diagnosis allows earlier bisphosphonate therapy and specialist intervention – significantly improving long-term outcomes. Find out more about differentiating soft bone conditions including rickets and osteomalacia in this SVK Herbal clinical explainer. (PMC – Delayed OI Diagnosis Case, 2022); (PMC – OI and Child Abuse Differential, 2021); (PMC – OI Physiotherapy Case, 2022)
References:
American Academy of Orthopaedic Surgeons. (2023). Osteogenesis imperfecta (brittle bone disease). OrthoInfo. https://orthoinfo.aaos.org/en/diseases–conditions/osteogenesis-imperfecta-brittle-bone-disease
Damam, S., Taksande, A., & Meshram, R. J. (2024). Integrative management of bone deformities in osteogenesis imperfecta: A case report on zoledronic acid and corrective osteotomy. Cureus, 16(10), e70880. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533567/
Dhage, P. P., & Wadhokar, O. C. (2022). Brittle bone disease (osteogenesis imperfecta): A rare condition. Pan African Medical Journal, 43, 11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674524/
Khatri, M., Naughton, R. J., Clifford, T., Harper, L. D., & Corr, L. (2021). The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: A systematic review. Amino Acids, 53(10), 1493-1506. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521576/
Lund, A. M., Hansen, F. J., & Fogh, I. (2020). COL1A1- and COL1A2-related osteogenesis imperfecta. In M. P. Adam, J. Feldman, & G. M. Mirzaa (Eds.), GeneReviews. National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/books/NBK1295/
MedlinePlus. (2024). Osteogenesis imperfecta. U.S. National Library of Medicine. https://medlineplus.gov/genetics/condition/osteogenesis-imperfecta/
Merck Manual Professional Edition. (2025). Osteogenesis imperfecta. https://www.merckmanuals.com/professional/pediatrics/connective-tissue-disorders-in-children/osteogenesis-imperfecta
Naturem. (2025). Joints+ capsules. https://naturem.us/products/joints-capsules
Nguyen, E. B., Kim, E. Y., Malwane, M. I., Trejo, S., & Cucalon-Calderon, J. R. (2022). Delayed diagnosis of osteogenesis imperfecta: A differential diagnosis guided by competing ocular findings and a lack of family history. Cureus, 14(6), e25822. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271314/
Nijhuis, W., Verhoef, M., van Bergen, C., Weinans, H., & Sakkers, R. (2022). Fractures in osteogenesis imperfecta: Pathogenesis, treatment, rehabilitation and prevention. Children, 9(2), 268. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869965/
Pillion, J. P., Vernick, D., & Shapiro, J. (2011). Hearing loss in osteogenesis imperfecta: Characteristics and treatment considerations. Scientific World Journal, 2011, 983942. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335494/
Rodriguez Celin, M., Steiner, R. D., & Basel, D. (2023). COL1A1- and COL1A2-related osteogenesis imperfecta. In M. P. Adam, J. Feldman, & G. M. Mirzaa (Eds.), GeneReviews. National Center for Biotechnology Information. https://pubmed.ncbi.nlm.nih.gov/20301472/
Semler, O., Garbes, L., Keupp, K., Swan, D., Zimmermann, K., Dorow, J., & Wirth, B. (2012). A mutation in the 5′-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. American Journal of Human Genetics, 91(2), 349-357. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151368/
Altalib, A., Althomali, A., Alshahrani, A., Alfrayyan, A., & Aljughaiman, M. S. (2021). Osteogenesis imperfecta and child abuse from a forensic point of view. Cureus, 13(1), e12790. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891677/
Tauer, J. T., Robinson, M. E., & Bhanu Bhanu Bhanu Bhanu, S. (2019). Osteogenesis imperfecta: Clinical and treatment aspects. Current Osteoporosis Reports, 17(2), 49-57. https://pmc.ncbi.nlm.nih.gov/articles/PMC8533546/
Wang, M., Yuanyuan, L., Kaito, T., & Ohba, S. (2021). Restoration of osteogenesis by CRISPR/Cas9 genome editing of the mutated COL1A1 gene in osteogenesis imperfecta. Molecular Therapy – Nucleic Acids, 24, 378-385. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307903/
Wijaya, T. W., Wijaya, R., & Tan, L. T. (2021). Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database of Systematic Reviews, 2019(12), CD005088. https://pmc.ncbi.nlm.nih.gov/articles/PMC6611487/
Yilmaz, D., Karakaya, A., Turan, S., Bereket, A., & Guran, T. (2023). Osteoporosis improved by romosozumab therapy in a patient with type I osteogenesis imperfecta. AACE Clinical Case Reports, 9(6), 186-188. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690408/
Zhytnik, L., Maasalu, K., Duy, B. H., Pashenko, A., Khmyzov, S., Reimann, E., & Martson, A. (2019). COL1A1/2 pathogenic variants and phenotype characteristics in Ukrainian osteogenesis imperfecta patients. Human Genomics, 13(1), 42. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696896/